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The term "latency" is often applied to infections caused 
by herpesviruses, wherein viral replication and disease 
manifestations appear concordantly after long intervals of 
silence. In the case of the human immunodeficiency virus 
(HIV), an asymptomatic period of "clinical latency" can in- 
tervene between infection and the development of the 
acquired immune deficiency syndrome (AIDS). Freedom 
from symptoms does not, however, imply an absence of 
viral replication. Recent experiments tudying the kinetics 
of viral turnover have estimated that, in patients with CD4 
counts of 500 or less, 10~-109 virions are produced per 
day, resulting in a peripheral viremia of 104-107 RNA mole- 
cules/ml and in the destruction of approximately 2 x 109 
CD4 ÷ T cells/day (Ho et al., 1995; Wei et al., 1995). Most 
(>98%) of the plasma virus is apparently produced within 
recently infected cells, with little contribution from chroni- 
cally infected cells or from latently infected cells that then 
become activated. On the basis of these studies, the possi- 
bility has been raised that the kinetics of viral and cellular 
turnover found in late-stage disease may persist from the 
outset, leading ultimately to immune system collapse and 
AIDS (Coffin, 1995). If so, then cells with latent viral ge- 
nomes may be inconsequential to disease progression. 
This view of "virological mayhem" (Wain-Hobson, 1995) 
may be correct, but it is currently an inference. The kinetics 
of viral and cell turnover in late-stage disease were de- 
duced upon perturbation of the steady state with combina- 
tions of antiretroviral compounds. For populations of pa- 
tients with early-stage and asymptomatic disease, data 
from such an intervention have yet to be reported. Indeed, 
this phase of disease appears to be associated not simply 
with clinical latency, but also with easily detectable levels 
of cells with latent viral genomes. In this review, previous 
findings on viral latency in HIV disease are discussed in 
relation to emerging paradigms of persistent and high level 
viral replication and cytopathicity. 
Quantitative Changes in Virus Load During 
Disease Progression 
In most HIV-infected patients, the absolute level of viremia 
may fluctuate, but active virus replication clearly persists 
throughout he disease course. The acute viral syndrome 
that sometimes follows primary exposure is associated 
with high peak levels of cell-associated and cell-free virus 
in the peripheral blood (Clark et al., 1991; Daar et al., 1991; 
Graziosi et al., 1993). Most patients thereafter move into 
an asymptomatic phase of disease in which absolute lev- 
els of HIV RNA in the peripheral blood are lower but still 
demonstrable (Piatak et al., 1993). Even at times when 
detectable virus in the peripheral circulation is at a nadir, 
high levels of virus replication and of "trapped" extracellu- 
lar virus (e.g., on follicular dendritic cells) are found within 
lymphoid organs (Fox et al., 1991; Pantaleo et al., 1991, 
1993; Embretson et al., 1993a). As measu red by infectious 
virus titers and levels of p24 antigen or viral nucleic acid, 
there is a positive correlation between clinical stage and 
the absolute level of virus replication (Coombs et al., 1989; 
Ho et al., 1989; Schnittman et al., 1991; Michael et al., 
1992; Piatak et al., 1993). This is true whether the mea- 
surements are performed in peripheral blood or within 
hematolymphoid organs. The latter, however, tend to be 
preferential sites for replication and the repository of most 
CD4 ÷ cells in the body. It is within these organs, presum- 
ably, that most virus replication occurs. 
Latency at the Cellular Level 
Though HIV replication may be chronically persistent 
within infected individuals, cells carrying latent genomes 
are also found. This point was perhaps best demonstrated 
in studies of HIV-infected chimpanzees: active viral repli- 
cation was detected in lymphoid organs, while cells with 
transcriptionally silent but inducible HIV genomes circu- 
lated in the peripheral blood (Saksela et al., 1993). Such 
latency is likely associated with the fact that most CD4 ÷ 
cells are resting in vivo, a function of strong checks on 
cell division within the hematopoietic system. 
Formally, two latent states have been envisioned for the 
viral genome. 
Preintegration Latency 
Like other lentiretroviruses, HIV may bind to and enter 
quiescent arget cells (Stevenson et al., 1990a; Zack et al., 
1990). With participation from nuclear localizing signals on 
the viral proteins Vpr and matrix, the viral preintegration 
complex is actively transported through the nucleopore 
(Bukrinsky et al., 1993; Heinzinger et al., 1994; von Schwed- 
ler et al., 1994; Gallay et al., 1995). In terminally differenti- 
ated macrophages and cells that are arrested in the GI/  
S or G2 phases of the cell cycle, HIV replication can occur 
after proviral integration (Weinberg et al., 1991; Lewis et 
al., 1992; Lewis and Emerman, 1994). In contrast, integra- 
tion does not occur within T lymphocytes that are in the 
GO phase of the cell cycle. Extrachromosomal replicative 
intermediates remain unintegrated in the cell for a limited 
period of hours to days (Zack et al., 1990; Stevenson et 
al., 1990a) and, although the data are controversial (Sakai 
et al., 1993), may even serve as competent emplates for 
the production of HIV-1 core and envelope proteins (Ste- 
venson et al., 1990b). Until and unless the cell is activated, 
proviral integration and virus production do not occur. 
Since CD4 ÷ cells are normally quiescent in vivo, preinte- 
gration latency in T cells may occur frequently within the 
HIV-infected patient. Unintegrated viral DNA has indeed 
been documented both within quiescent peripheral blood 
T cells (Bukrinsky et al., 1991) and in microglial cells of 
the central nervous system (Pang et al., 1990). In the for- 
mer case, these genomes were shown to retain the ability 
to integrate after activation of the host cell. However, the 
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half-life of the unintegrated genome is short, relative to 
the estimated division time of resting T cells in vivo 
(McLean and Michie, 1995), and the stable integration of 
such genomes in vivo is likely a rare event. 
Postintegration Latency 
The human T lymphoblastoid cell line, ACH-2, and the 
myeloid line, U 1, harbor integrated viral genomes in a mini- 
mally productive state and have sewed as in vitro models 
for postintegration latency. Upon exposure of these lines 
to tumor necrosis factor (~ (TNFa) and phorbol esters, virus 
production occurs via NF-KB-mediated induction of the 
HIV-1 long terminal repeat (Dub et al., 1989; Folks et al., 
1989; Griffin et al., 1989). Early studies indicated that cells 
within these lines express multiply spliced transcripts as- 
sociated with viral regulatory gene products in the absence 
of full-length genomic RNA (Pomerantz et al., 1990). This 
"blocked early-stage latency" pattern of transcription in 
vitro, equivalent o the early stages of a lytic infection (Kim 
et al., 1989), was postulated to be maintained by limiting 
intracellular levels of the viral regulatory protein Rev. This 
situation approximates the state of latency previously 
shown for lentiretroviruses uch as visna virus, in which 
large numbers of infected cells produce viral RNA but not 
virus (Gendelman et al., 1985). 
Different mechanisms of latency have been documented 
within these cell line models. Latency in U1 cells appears 
to result, at least in part, from a relative deficiency of Tat 
in the cellular environment (Chen et al., 1994) and is asso- 
ciated with an accumulation of promoter-proximal viral 
transcripts (Adams et al., 1994). Provision of Tat protein 
overcomes the latent state (Cannon et al., 1994; Duan et 
al., 1994). In contrast, critical determinants of latency in 
ACH-2 appear to reside at the site of integration (Winslow 
et al., 1993; Chen et al., 1994), and very low levels of 
transcription in this line are not up-regulated by exogenous 
Tat protein (Cannon et al., 1994; Duan et al., 1994). 
In HIV-infected patients, cells carrying integrated provi- 
rus in a latent state are readily demonstrable. Early studies 
indicated that cells with latent genomes were 10- to 100- 
fold more abundant than those actively replicating viral 
RNA (Harper et al., 1986; McEIrath et al., 1989; Psalli- 
dopoulos et al., 1989; Schnittman et al., 1989). Among 
infected cells in which HIV was transcriptionally active, 
many were found to not produce viral structural gene prod- 
ucts (Namikawa et al., 1988). Subsequent studies using 
a variety of assays (including standard in situ hybridization 
as well as flow cytometry and polymerase chain reaction- 
driven detection of viral DNA and RNA in situ) confirmed 
a high frequency of cells carrying viral DNA in vivo and a 
correspondingly low frequency of cells actively transcrib- 
ing viral RNA (Bagasra and Pomerantz, 1993; Embretson 
et al., 1993a, 1993b; Pantaleo et al., 1993; Patterson et 
al., 1993; Lebargy et al., 1994). These observations were 
made in lymphoid and myeloid cells obtained from periph- 
eral blood, lymphoid organs, and by bronchoalveolar la- 
vage. In accordance with the in vitro model systems for HIV 
latency, peripheral blood cells obtained from HIV ÷ patients 
were found in some (Michael et al., 1992; Seshamma et 
al., 1992) but not all (Saksela et al., 1994) studies to exhibit 
"blocked early-stage latency," with a predominance of mul- 
tiply spliced over unspliced or singly spliced viral RNAs. 
HIV-infected cells with a bias toward promoter-proximal 
transcripts were also observed (Adams et al., 1994). 
As a special case, some integrated genomes may be 
defective and replication incompetent. In at least one in- 
stance, such defects have been associated with a pro- 
longed state of clinical well-being and mapped to muta- 
tions in the nef gene (Kirchhoff et al., 1995). Although 
undocumented, it is conceivable that production of viral 
gene products, if not viral progeny, from such genomes 
could have deleterious effects to the host cell, neighboring 
cells, or both. 
Balancing Latency and Replication in Vivo 
Data from the above studies broadly define four cell popu- 
lations in the H IV-infected host: one that actively produces 
virus, another that carries latent proviral genomes, a third 
that carries defective proviral genomes, and a fourth that 
differentiates and/or proliferates to compensate for losses 
within the former populations. Since these cell populations 
reside primarily in hematolymphoid organs, it is difficult 
to measure their size and turnover. The recent studies of 
viral turnover by Wei et al. (1995) and Ho et al. (1995) 
provide some estimates in late-stage disease (see above). 
To date, however, no firm estimates of the size and relative 
proportions of these populations are available for early- 
stage HIV disease (i.e., when peripheral blood CD4 counts 
are greater than 500 and circulating viral loads less than 
104 RNA molecules/ml). It is only evident that stable num- 
bers of circulating CD4 ÷ T cells can be observed du ring this 
"clinically latent" period. To understand how this balance is 
maintained and possibly lost, it is instructive to consider 
its formation. 
Irrespective of the route of introduction, the initial inocu- 
lure of HIV is likely to be small and focally deposited within 
lymphoreticular tissue that drains the port of entry (McCune, 
1991). Since the virus carries many antigenic epitopes 
(and may be accompanied by allogeneic cells and other 
potent polyclonal activators), the immunocompetent host 
will mount an immune response involving interactions be- 
tween antigen-presenting cells, T cells, and B cells. Para- 
doxically, CD4 + T cell activation during these responses 
will create favorable conditions for infection, integration, 
and dissemination of HIV (Pope et al., 1994). Viral spread 
may occur because the cell is productively infected. Alter- 
natively, naive CD4 + T cells may move through one round 
of division, integrate proviral genomes, and then remain 
quiescent as CD4 ÷ memory cells. If so, the potential for 
viral spread will move with the cell itself. 
The total body deposition of virus during acute infection 
will be determined in part by the rate of viral replication and 
the counterposing effectiveness of the antiviral immune 
response. At its end, a fraction of the CD4 + target cell 
population will carry HIV genomes. Ongoing virus produc- 
tion will occur in some of these cells (e.g., macrophages 
and activated T cells). This fraction of cells may rapidly 
turn over and, in the process, establish an ever-expanding 
cohort of secondarily infected target cells. Such a scenario 
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would be consistent with the dynamics of viral replication 
and cell turnover observed in late stages of disease. How- 
ever, since most infected target cells will be quiescent, 
HIV genomes at this time may instead be deposited pre- 
dominantly within a state of preintegration latency (e.g., 
in the case of infected T cells that have not divided) or 
postintegration latency (e.g., in the case of T cells that 
have divided at least once postinfection). These latent ge- 
nomes will have differential stability: those that are uninte- 
grated may be degraded quickly and lost from the cell; 
those that are integrated could potentially remain for the 
lifetime of the quiescent cell. 
Changes in the total body load of HIV will thereafter be 
determined, in part, by the rate of clearance of productively 
infected cells, the rate of virus release from these cells, 
and the rate by which cells with latent genomes are 
cleared. In some infected patients, disease progression 
after the acute viral syndrome occurs slowly, if at all (Cao 
et al., 1995; Pantaleo et al., 1995). In a few patients, virus 
may even be cleared entirely (Clerici et al., 1992; Rowland- 
Jones et al., 1993; Bryson et al., 1995). The mechanisms 
underlying these phenomena are poorly understood, but 
could include slow or defective viral replication, the devel- 
opment of rapidly effective antiviral immune responses, 
or both. 
Cellular Latency Lost 
Several correlations uggest that disease progression is 
associated with a relative change in the proportion of cells 
carrying latent genomes and of those that actively repli- 
cate virus. First, the putative mechanisms for cellular la- 
tency have been most readily observed in cross-sectional 
studies of patients with early, asymptomatic disease. Sec- 
ondly, prospective studies have revealed a time-dependent 
loss of cellular latency as disease progresses. In periph- 
eral blood mononuclear cells, advancing disease was 
predated by a qualitative change from no to measurable 
(Saksela et al., 1994) or from predominantly spliced to 
unspliced (Michael et al., 1995) viral RNA production. By 
analogy with studies of lymphoid organs (Embretson et 
al., 1993a; Pantaleo et al., 1993), this may reflect an even 
greater shift away from latency within lymphoid compart- 
ments. 
This shift may occur because the physiological environ- 
ment of progressive HIV disease disfavors the mainte- 
nance of quiescent cells carrying latent genomes. Exposure 
to antigenic challenges (e.g., chronic parasitic infections, 
common colds, and even vaccinations) will prompt cellular 
proliferation and viral replication. Besides stimulating spe- 
cific immune responses (and thereby clonally activating 
CD4 + T cells), infectious agents may also shift the balance 
between latent and productive infection by triggering the 
production of cytokines that can up-regulate HIV replica- 
tion (e.g., interleukin-1 or TNFa) (Poli and Fauci, 1992). 
In some cases (e.g., the CD4 ÷ T tropic human herpesvirus 
6), direct transactivation of the otherwise latent HIV ge- 
nome can also occur (Kashanchi et al., 1994). 
Once initiated, the various endogenous and exogenous 
signals leading to cell activation will drive a self-per- 
petuating and slowly progressive loop. Movement of a cell 
toward viral replication is associated with the production 
of the following: vitally encoded proteins capable of driving 
de novo immune responses; Tat, which can drive the pro- 
duction of cytokines (e.g., TNFa) (Sastry et al., 1990) and 
secondarily up-regulate virus production in other latently 
infected cells (Folks et al., 1989; Kitano et al., 1993); Vpr, 
which can up-regulate viral replication in T cells and mac- 
rophages (Levy et al., 1995); Nef, which can render viral 
particles more infectious (Miller et al., 1994). Each of these 
influences will serve to expand the population of produc- 
tively infected cells. 
Since most productively infected cells appear to have 
a short iifespan (Ho et al., 1995; Wei et al., 1995), constant 
levels of CD4 + cells in the peripheral blood must be main- 
tained by enhanced hematopoietic activity. This could oc- 
cur upon accelerated differentiation and proliferation of 
early hematopoietic progenitor cells in the bone marrow 
or thymus and/or by proliferation of clonally dispersed T 
cells in the periphery. In either case, feedback stimulation 
on the hematopoietic system will have mixed effects. The 
generation of functional cells de novo serves to restore 
the peripheral immune system; reciprocally, moving more 
CD4 ÷ hematopoietic ells into cycle will create a larger 
pool of cells susceptible to HIV infection and destruction. 
At the level of the primitive multilineage hematopoietic 
stem cell, some of the very cytokines that up-regulate virus 
production (e.g., TNF~, TGFI~, and interferon-y) can also 
serve to suppress multilineage hematopoiesis (McCune 
and Kaneshima, 1995). 
Interesting twists to the above dynamics are presented 
by hosts with less functional immune systems, e.g., the 
HIV-infected fetus. In comparison with the immunocompe- 
tent adult, immune system activation will not be as wide- 
spread: exogenous antigens are absent and infection of 
the thymus may even induce a state of tolerance toward 
HIV. Predictably, most CD4 ÷ T cells will be quiescent at 
birth and latent proviral genomes should prevail within 
them. In contrast, a higher proliferative mass is likely to 
be found in the hematopoietic progenitor cell compartment 
of the developing fetus. CD4 + cells in this group of progeni- 
tors (e.g., CD3-CD4+CD8 - intrathymic T progenitors) may 
accordingly be more susceptible to productive infection 
and destruction by HIV (Suet al., 1995). 
Concluding Remarks 
The cellular dynamics of HIV disease are complex: in- 
fected cells with productive or latent genomes can coexist 
even in the absence of apparent signs or symptoms. Cells 
with latent genomes may represent a minor fraction of the 
total number of infected cells or may often carry defective 
genomes. If so, they may constitute an unimportant reser- 
voir for virus spread in vivo, at least as extrapolated from 
a "steady-state" analysis of late-stage disease (Coffin, 
1995). Alternatively, since asymptomatic HIV disease may 
be associated with fewer proliferative signals (e.g., from 
opportunistic infections, induced cytokines, etc.), resting 
cells with latent, replication-competent genomes may pre- 
vail during the early stages of disease. These genomes 
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may then be induced toward viral production as disease 
progresses. With further rounds of viral replication and 
mutation, it is possible that this compartment of resting 
cells may later carry a predominance of genomes that are 
either defective or, alternatively, resistant to the action of 
antiviral compounds. 
Discrimination between these possiblities will be im- 
portant for the rational design of treatment protocols for 
HIV disease. Should cells with actively replicating virus 
be abundant and persistent throughout the course of dis- 
ease, a plausible argument may be made for early and 
aggressive therapy with combinations of effective antiret- 
roviral compounds. This approach would, of course, be 
less compell ing if latent genomes predominate during 
early stages of disease. 
At this juncture in our analysis of HIV pathogenesis, 
it is important to analyze carefully and quantitatively the 
contribution that various populations of HIV-infected cells 
may make toward disease progression. Where are these 
cells located? What state of latency do they maintain? 
How many are there? How long do they persist? What 
is their relative representation among the total infected 
population of cells? Having addressed these questions in 
adults, are there significant differences found in HIV- 
infected infants? Answers to these questions should help 
to clarify the role, if any, that cellular latency may play in 
HIV disease. 
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